anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An aqueous pharmaceutical composition for application to the mucosa, such as the nasal mucosa. The composition comprises ciclesonide and one or more water-insoluble and or water-low soluble substance (such as cellulose). The composition has an osmotic pressure of less than 290 mOsm. The composition may also have the following excipients: - An osmotic pressure-controlling agent, such as sodium chloride or a water soluble sugar such as glucose. - A water soluble polymer substance such as alginic acid, propylene glycol, pectin, guar gum and hydroxypropyl cellulose. - A surfactant such as polysorbate 80.
ACE-inhibitors: Reports suggest that NSAIDs may diminish the antihypertensive effect of ACE-inhibitors. This interaction should be given consideration in patients taking NSAIDs concomitantly with ACE-inhibitors. 

Antacids and Sucralfate: Concomitant administration of some antacids (magnesium oxide or aluminum hydroxide) and sucralfate can delay the absorption of naproxen. 

Aspirin: When naproxen as naproxen sodium is administered with aspirin, its protein binding is reduced, although the clearance of free naproxen sodium is not altered. The clinical significance of this interaction is not known; however, as with other NSAIDs, concomitant administration of naproxen and naproxen sodium and aspirin is not generally recommended because of the potential of increased adverse effects. 

Cholestyramine: As with other NSAIDs, concomitant administration of cholestyramine can delay the absorption of naproxen. 

Diuretics: Clinical studies, as well as post marketing observations, have shown that naproxen sodium can reduce the natriuretic effect-of furosemide and thiazides in some patients. This response has been attributed to inhibition of renal prostaglandin synthesis. During concomitant therapy with NSAIDs, the patient should be observed closely for signs of renal failure (see WARNINGS, Renal Effects), as well as to assure diuretic efficacy. 

Lithium: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance. The mean minimum lithium concentration increased 15% and the renal clearance was decreased by approximately 20%. These effects have been attributed to inhibition of renal prostaglandin synthesis by the NSAID. Thus, when NSAIDs and lithium are administered concurrently, subjects should be observed carefully for signs of lithium toxicity. 

Methotrexate: NSAIDs have been reported to competitively inhibit methotrexate accumulation in rabbit kidney slices. Naproxen, naproxen sodium and other nonsteroidal anti-inflammatory drugs have been reported to reduce the tubular secretion of methotrexate in an animal model. This may indicate that they could enhance the toxicity of methotrexate. Caution should be used when NSAIDs are administered concomitantly with methotrexate. 

Warfarin: The effects of warfarin and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than users of either drug alone. No significant interactions have been observed in clinical studies with naproxen and coumarin-type anticoagulants. However, caution is advised since interactions have been seen with other nonsteriodal agents of this class. The free fraction of warfarin may increase substantially in some subjects and naproxen interferes with platelet function.
PROBLEM TO BE SOLVED: To provide a double-stranded ribonucleic acid (dsRNA) targeting a transthyretin (TTR) gene, and a method for using the dsRNA to inhibit expression of TTR.SOLUTION: A double-stranded ribonucleic acid (dsRNA) for inhibiting expression of transthyretin (TTR) comprises a sense strand and an antisense strand. The antisense strand comprises a region complementary to a part of a mRNA encoding TTR. The region of complementarity is less than 30 nucleotides in length. In addition, the sense strand and the antisense strand include nucleotides having specific sequences, respectively. According to the present invention, there is also provided a pharmaceutical composition comprising the dsRNA. Here, the disorder is transthyretin amyloidosis.SELECTED DRAWING: None
BACKGROUND: We employed Mendelian randomization (MR) to investigate the causal relationship between the gut microbiota and lymphoid leukemia, further exploring the causal relationships among immune cells, lymphoid leukemia, and potential metabolic mediators.
METHODS: We utilized data from the largest genome-wide association studies to date, encompassing 418 species of gut microbiota, 713 types of immune cells, and 1,400 serum metabolites as exposures. Summary statistics for lymphoid leukemia, acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL) were obtained from the FinnGen database. We performed bidirectional Mendelian analyses to explore the causal relationships among the gut microbiota, immune cells, serum metabolites, and lymphoid leukemia. Additionally, we conducted a two-step mediation analysis to identify potential intermediary metabolites between immune cells and lymphoid leukemia.
RESULTS: Several gut microbiota were found to have causal relationships with lymphoid leukemia, ALL, and CLL, particularly within the Firmicutes and Bacteroidetes phyla. In the two-step MR analysis, various steroid hormone metabolites (such as DHEAS, pregnenolone sulfateprogestogen derivatives, and androstenediol-related compounds) were identified as potential intermediary metabolites between lymphoid leukemia and immune cells. In ALL, the causal relationship between 1-palmitoyl-2-docosahexaenoyl-GPE (16:0/22:6) and ALL was mediated by CD62L-plasmacytoid DC%DC (mediated proportion=-2.84%, P=0.020). In CLL, the causal relationship between N6,n6,n6-trimethyllysine and CLL was mediated by HLA DR+ CD8br AC (mediated proportion=4.07%, P=0.021).
CONCLUSION: This MR study provides evidence supporting specific causal relationships between the gut microbiota and lymphoid leukemia, as well as between certain immune cells and lymphoid leukemia with potential intermediary metabolites.
The present invention discloses traditional Chinese medicine tablets for treating hyperlipidemia, and a preparation method of the traditional Chinese medicine tablets. The tablets of the present invention are prepared from hawthorn (whose kernel is removed), prepared fleeceflower root, semen cassiae torae and lotus leaf. The semen cassiae torae and the hawthorn are put in water to be decocted for two times, and the semen cassiae torae and the hawthorn are decocted for 2 hours every time; the decocted solutions are mixed and filtered, and then, the filtered solution is concentrated into paste; the lotus leaf and the prepared fleeceflower root are extracted for three times by ethanol whose concentration is 50% in a refluxing mode, the ethanol is recovered and concentrated into paste, and then, the filtered solution paste and the ethanol paste are mixed; the pressure of the mixture is reduced, and the mixture is dried and pulverized into fine powder; a proper quantity of pre-gelatinizing starch and sodium carboxymethyl starch are added into the fine powder to be evenly mixed, the mixture is granulated by ethanol whose concentration is 75%, dried and pressed into tablets, and then, films are coated on the tablets to form finished products. The tablets of the present invention farthest keep effective components, and are convenient to take; the tablets of the present invention can be used for many people to take, and the dosage is accurate. Because the films which can be dissolved in the stomach are coated on the tablets, the stability of the tablets is improved; meanwhile, the bitterness of original medicines can be eliminated. The tablets of the present invention have the efficiency of reducing blood fat and softening blood vessels, and is used for enhancing the blood circulation of the coronary artery and resisting arrhythmia and hyperlipidemia.
Radiation-induced mucositis is an acute reaction of the mucosa of patients undergoing head and neck radiotherapy.It can lead to dose-limiting and debilitating side effect. There is no guideline on an acknowledged intervention that significantly reduces its severity. In the mucosa, the immune system's T cells and B cells have position-specific phenotypes and functions that are influenced by the microbiota. These cells play pivotal parts in the maintenance of immune homeostasis by suppressing responses to harmless antigens and by enforcing the integrity of the barrier functions of the gut mucosa.We designed a randomized trial of Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules in patients with Nasopharyngeal Carcinoma. The aim of this study was to determine if regulating intestinal tract flora was effective in reducing the severity of radiation-induced mucositis in patients receiving radical dose radiotherapy. The effect of this intervention on a patient's general well-being was also investigated. The primary end-point of the study was the incidence of Radiation Therapy Oncology Group grade 3 mucositis.In 2017, 40 patients are estimated to be recruited into the study at Jiangxi Cancer Hospitals, China.20 patients were randomized to receive Live Combined Bifidobacterium,Lactobacillus and Enterococcus Capsules and 20 to receive a placebo.
Critically ill patients, especially those that require endotracheal intubation, have the greatest risk of any hospitalized patient for acquiring nosocomial pneumonia. Nosocomial pneumonia, in this population, produces a substantial increase of mortality and morbidity. The literature suggests the causative pathway is aspiration of oropharyngeal pathogens found in dental plaque. The build-up of dental plaque has been significantly associated with subsequent nosocomial respiratory infections. Thus, prevention of pathogens colonization in the oropharyngeal cavity could be an effective infection control measure.

Dental plaque once it reaches a critical thickness, acts as a reservoir for both aerobic and anaerobic pathogens. Failure to remove plaque begins a complex cascade of biological activity by which pathogens adhere to mucosal and tooth surfaces and pathogen overgrowth ensues. Additionally, neglected or insufficient mouth care is the foremost predisposing factor to oral conditions such as gingivitis, mucositis, and stomatitis which supply additional ports of entry for pathogens.

There are only a handful of studies that compare the frequency and type of oral hygiene required to prevent or decrease oropharyngeal colonization. A recent pilot study, 01-CC-0207, compared oral care provision in two intensive care units (ICU) in the Clinical Center. The test ICU offered meticulous oral hygiene through a system of regular oral assessments taught by a dentist and dental hygienist. The score from the assessment determined the type and frequency of oral care. The control ICU gave standard care typical of the ICU community. Plaque and saliva assays were collected from the enrolled patients. Significantly lower Beck scores and lower colony forming organisms in the specimens was achieved in the test ICU on day 3, p less than 0.03 and p less than 0.001 respectively.

This protocol will expand the pilot into a prospective randomized assigned trial conducted at four hospitals in the Washington D.C. area. These hospitals have ICUs more representative of ICU's nation-wide. This study will test the effectiveness of a comprehensive and systematic oral care program to reduce the oral assessment scores, mucosal plaque scores, and the amount of pathogen inoculum present in the saliva and plaque. Intubated and non-intubated patients will be compared as well as meticulous care with or without the addition of the oral antiseptic, chlorhexidine. Consistency of practice performance will also be evaluated when nursing staff has dentist/hygienist instruction and monitoring versus the traditional nurse instruction.
After the 1-week run-in period, participants in the control group will be provided with constant daily step goals that were set to 10,000 steps per day through the Sprout app. Participants will receive a push notification at 8 AM every day that provides that day's step goal (10,000 steps), and if the participant achieves the goal before 8 PM, then another push notification will be sent to congratulate the participant on reaching their step goal (of 10,000 steps) for the day.
PURPOSE: An eye make-up cosmetic composition containing water-soluble silicone compounds is provided to minimize dryness as time goes by fixing moisuture inside the cosmetic material. CONSTITUTION: An eye make-up cosmetic composition contains water-soluble silicone compounds. The water-soluble silicone compound is represented by chemical formula 1. In the chemical formula 1, Xn1 indicates hydrophilic polymer, and n1 indicates an integer of 10-20. R1 and R2 respectively and independently indicates hydrocarbon group having 1-20 carbons which includes functional group of alcohol group, CHO group, carboxylic acid group, ether group, ketone group, ester and amine group. n2 indicates an integer of 1-20. 0.1-20 weight% of the water soluble silicon compound is contained based on the total weight of the cosmetic composition. The cosmetic composition increases volume force, application properties, spread prevention properties, curling force or semi-drying properties. The cosmetic composition is formed into a mascara form.
An attempt to identify the human counterpart of murine macrophage inflammatory protein 2 unexpectedly resulted in not one but two candidate sequences, designated hu-MIP-2.alpha. and hu-MIP-.beta., respectively. By using the DNA sequences and recombinant systems provided by this invention, one can obtain hu-MIP-2.beta., one of the two human counterparts to mMIP-2, substantially free of other human protein. This invention also provides antibodies reactive with hu-MIP-2$(b) polypeptides as well as immunoassay methods for determining hu-MIP-2.beta. and nucleotide probes for detecting nucleotide sequences encoding hu-MIP-2.beta. in biological samples.
The described agglomeration of drug microparticles blended with excipient microparticles is a technique for the size enlargement of micronized products that could be damaged by granulation or compaction techniques. These agglomerates can be used as oral prompt or delayed-release dosage forms administered as they are or dispersed in a liquid. The composition and quantity of the excipient microparticles resulted to be the crucial factors for the agglomerate quality. Therefore, adjusting the content of surface-active agent between 8-20%, of the excipient microparticles it is possible to agglomerate microparticles of drugs that could not be agglomerated per se. Increasing the surfactant concentration in the spray-dried excipient microparticles or increasing the fraction of these excipient microparticles in the blend, the agglomeration was improved. The spray drying technique concentrates the surface-active agent on the microparticle surface. By tumbling, the surface-active agent present on microparticles excipient surface was spread to fill the inter-particle interstices of drug particles giving rise to more resistant agglomerates. This phenomenon occurred also by vibration; the production in this case was quicker.
A dosage form comprises an active ingredient, a core having an outer surface and a first shape and a shell having outer and inner surfaces and a second shape, in which the shell surrounds at least a portion of the core, and the first and second shapes are substantially different. In one embodiment the shell comprises at least about 80% of a flowable material selected from the group consisting of film formers, gelling polymers, thermoplastic materials, low melting hydrophobic materials, non-crystallizable sugars, non-crystallizable sugar-alcohols, and mixtures thereof. In another embodiment the shell is substantially free of pores having a diameter of 0.5 to 5.0 microns. In another embodiment, the core and shell each having a different number of planes of symmetry with respect to the same reference axis. In another embodiment, the distance from the core outer surface to the shell outer surface is different at two different points located on the core outer surface and the difference is greater than about 125 microns. Either the core, the shell, or a combination thereof may contain at least one active ingredient. The core and shell may each be molded or compressed. The core may also comprise an insert which may contain at least one active ingredient. The shape of the core may be chosen so as to permit modified release of active material in the core upon breach of the shell or provides a modified release profile for the active material in the core.
The high-intensity intervaled exercise (HIIE) will bem performed divided into 3 phases: warm-up (10 minutes), main part (15 minutes) and cool down (5 minutes). The warm-up and cool down will be performed at 55-60% HRmax. The main part will last 15 minutes and will be performed by 2 sets of 5 exercises lasting 30 seconds to each exercise combined with 1 minute of active recovery. The exercise moment will be performed at 80-85% HRmax and the 1-minute active recovery at 55-60% HRmax. For both warm-up and cool down, HR will be measured every 2 minutes. For main part, HR will be measured at the end of each 30-seconds from exercise.
Alcohol 0.5 g/kg (vodka diluted in lemon-flavoured water), single dose, oral administration. Solution of 150 ml.
Intraveneous nutrient soln. for medical or veterinary use comprises (a) a carboxylate anti-microbial agent, excluding propionate; (b) a nutrient; and (c) pyrogen-free water. Used for maintaining unconscious patients, turn victims and gastromitestinal surgery patients. Presence of the antimicrobial agent prevents fungal contamination and thus infection of the patient. Nutrient solns. without an antimicrobial agent are ideal growth media for harmful microorganisms.
Those with vitamin D deficiency will be replaced with vitamin D3 at 1000 IU at the first visit. Vitamin D3 1000 IU is expected to increase blood 25-hydroxyvitamin-D level by 25 nmol/L. Blood 25-hydroxyvitamin-D level will be rechecked 3 months after replacement. If the blood 25-hydroxyvitamin-D level is still below 50 nmol/L, the vitamin D3 replacement dosage will be increased to 2000 IU.
Provides is a therapeutic technology that combines the phototoxic and immune-stimulating ability of photodynamic therapy with the widespread effectiveness of the immune system to reduce the viability of such as cancer cells and tumors. The nanoparticle compositions of the disclosure combine an immunostimulant with a photosensitizer using a nanoparticle delivery platform. For example, zinc pthalocyanine, which is a long-wavelength absorbing photosensitizer, integrated into a polymeric nanoparticle core made up of poly(D,L-lactic-co-glycolic acid)-b-poly(ethylene glycol) (PLGA-b-PEG). The outside surface of the core can be coated with metallic nanoparticles, which are then modified with CpG-ODN. Metastatic mouse breast carcinoma cells showed significant photocytotoxicity of the hybrid after irradiation with a 660 nm LASER light and this activity was remarkably better than either treatment alone. Treatment of mouse bone marrow derived dendritic cells with the photodynamic therapy-killed 4T1 cell lysate showed that the combination of photodynamic therapy with a synergistic immunostimulant in a single nanoparticle system resulted in an immune response suitable for the treatment of such as a metastatic cancer.
NEW MATERIAL:A fish growth hormone which is a polypeptide produced by culturing the pituitary body of a fish of Anguillidae family, and extracting and purifying the culture liquid. It has following properties. Amino acid sequence, shown by the formula; molecular weight, 23,000; isoelectric point, 6.3; solubility, soluble in alkaline aqueous solution and insoluble or hardly soluble in neutral and acidic aqueous solution; nature, acidic white powder. USE:Growth hormone for fish. PREPARATION:The pituitary body of a fish of Anguillidae family, preferably eel is extracted aseptically, cultured in a culture liquid (e.g. Eagle MEM culture liquid containing Earle's electrolyte) at 15-20 deg.C in an atmosphere consisting of 90-99% O2 and 1-10% CO2 for about 10 weeks changing the culture liquid once a week. The growth hormone polypeptide can be separated in purified state from the culture liquid by ultra-filtration, gel-filtration, chromatofocusing, etc. Since the hormone has growth-promotion effect on fish, it can be used in pisciculture.
BACKGROUND: The aim was to establish a 10-year dyslipidemia incidence model, investigating novel anthropometric indices using exploratory regression and data mining.
METHODS: This data mining study was conducted on people who were diagnosed with dyslipidemia in phase 2 (n = 1097) of the Mashhad Stroke and Heart Atherosclerotic Disorder (MASHAD) study, who were compared with healthy people in this phase (n = 679). The association of dyslipidemia with several novel anthropometric indices including Conicity Index (C-Index), Body Roundness Index (BRI), Visceral Adiposity Index (VAI), Lipid Accumulation Product (LAP), Abdominal Volume Index (AVI), Weight-Adjusted-Waist Index (WWI), A Body Shape Index (ABSI), Body Mass Index (BMI), Body Adiposity Index (BAI) and Body Surface Area (BSA) was evaluated. Logistic Regression (LR) and Decision Tree (DT) analysis were utilized to evaluate the association. The accuracy, sensitivity, and specificity of DT were assessed through the performance of a Receiver Operating Characteristic (ROC) curve using R software.
RESULTS: A total of 1776 subjects without dyslipidemia during phase 1 were followed up in phase 2 and enrolled into the current study. The AUC of models A and B were 0.69 and 0.63 among subjects with dyslipidemia, respectively. VAI has been identified as a significant predictor of dyslipidemias (OR: 2.81, (95% CI: 2.07, 3.81)) in all models. Moreover, the DT showed that VAI followed by BMI and LAP were the most critical variables in predicting dyslipidemia incidence.
CONCLUSIONS: Based on the results, model A had an acceptable performance for predicting 10 years of dyslipidemia incidence. Furthermore, the VAI, BMI, and LAP were the principal anthropometric factors for predicting dyslipidemia incidence by LR and DT models.
INTRODUCTION: Incontinence is a common, distressing condition, most prevalent in older people. There is an unmet need for effective interventions to support continence. This review focuses on non-pharmacological interventions to reduce incontinence among homebound older people. Aim: to identify interventions with potential to be delivered by care workers, nurses or family members in a person's home.
METHODS: Multiple databases were searched until 15 September 2023 for randomised controlled trials reporting home-based interventions for incontinence for older people (≥65 years) living at home. Two reviewers independently screened titles, abstracts and papers against inclusion criteria, then assessed for the Risk of Bias (RoB2). A third reviewer resolved the discrepancies. Primary data were extracted and synthesised.
RESULTS: A full-text review of 81 papers identified seven eligible papers (1996-2022, all USA), including n = 636 participants (561 women and 75 men). Two studies focusing on multicomponent behavioural interventions showed benefit, as did one study of transcutaneous tibial nerve stimulation self-administered through electrode-embedded socks. Three, which included cognitively impaired people, reported improvement with toileting assistance programmes, but the effects were not all significant. Results were inconclusive from a study examining the effects of fluid intake adjustments. Interventions were delivered by nurses, three in collaboration with family caregivers. No faecal incontinence interventions met the criteria.
CONCLUSION: There is scant evidence for continence supporting interventions delivered in older people's own homes. With an ageing population often reliant on family or social care workers well-placed to support continence promotion and policy drives for services to support older people remaining at home, this evidence gap needs addressing.